JP2020532535A - セピアプテリンを含む医薬組成物及びその使用 - Google Patents

セピアプテリンを含む医薬組成物及びその使用 Download PDF

Info

Publication number
JP2020532535A
JP2020532535A JP2020512443A JP2020512443A JP2020532535A JP 2020532535 A JP2020532535 A JP 2020532535A JP 2020512443 A JP2020512443 A JP 2020512443A JP 2020512443 A JP2020512443 A JP 2020512443A JP 2020532535 A JP2020532535 A JP 2020532535A
Authority
JP
Japan
Prior art keywords
sepiapterin
pharmaceutical composition
composition according
crystal
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020512443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532535A5 (cg-RX-API-DMAC7.html
Inventor
ダニエル， イー． レヴィー，
ダニエル， イー． レヴィー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics MP Inc
Original Assignee
Censa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Censa Pharmaceuticals Inc filed Critical Censa Pharmaceuticals Inc
Publication of JP2020532535A publication Critical patent/JP2020532535A/ja
Publication of JP2020532535A5 publication Critical patent/JP2020532535A5/ja
Priority to JP2023088749A priority Critical patent/JP2023116556A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020512443A 2017-09-01 2018-09-04 セピアプテリンを含む医薬組成物及びその使用 Pending JP2020532535A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023088749A JP2023116556A (ja) 2017-09-01 2023-05-30 セピアプテリンを含む医薬組成物及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762553603P 2017-09-01 2017-09-01
US62/553,603 2017-09-01
US201862678069P 2018-05-30 2018-05-30
US62/678,069 2018-05-30
PCT/US2018/049359 WO2019046849A1 (en) 2017-09-01 2018-09-04 PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023088749A Division JP2023116556A (ja) 2017-09-01 2023-05-30 セピアプテリンを含む医薬組成物及びその使用

Publications (2)

Publication Number Publication Date
JP2020532535A true JP2020532535A (ja) 2020-11-12
JP2020532535A5 JP2020532535A5 (cg-RX-API-DMAC7.html) 2021-10-14

Family

ID=65526057

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512443A Pending JP2020532535A (ja) 2017-09-01 2018-09-04 セピアプテリンを含む医薬組成物及びその使用
JP2023088749A Pending JP2023116556A (ja) 2017-09-01 2023-05-30 セピアプテリンを含む医薬組成物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023088749A Pending JP2023116556A (ja) 2017-09-01 2023-05-30 セピアプテリンを含む医薬組成物及びその使用

Country Status (8)

Country Link
US (3) US11752154B2 (cg-RX-API-DMAC7.html)
EP (1) EP3675863A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020532535A (cg-RX-API-DMAC7.html)
CN (1) CN111491635A (cg-RX-API-DMAC7.html)
BR (1) BR112020003865A8 (cg-RX-API-DMAC7.html)
CA (1) CA3073957A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020002271A (cg-RX-API-DMAC7.html)
WO (1) WO2019046849A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130197000A1 (en) 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
WO2018102314A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
AU2017366879C1 (en) 2016-11-29 2022-08-11 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
BR112020003865A8 (pt) 2017-09-01 2022-08-16 Censa Pharmaceuticals Inc Composições farmacêuticas compreendendo sepiapterina e seus usos
MX2020012978A (es) 2018-05-30 2021-04-28 Ptc Therapeutics Mp Inc Sales de sepiapterina farmacéuticamente aceptables.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
SMT202400430T1 (it) 2018-05-30 2024-11-15 Ptc Therapeutics Mp Inc Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina
SMT202500089T1 (it) 2019-08-05 2025-03-12 Univ Virginia Commonwealth Uso di sepiapterina e suoi metaboliti per trattare una esposizione alle radiazioni
LT4034122T (lt) * 2019-09-25 2025-11-10 Hiperfenilalaninemijos gydymo būdai
WO2021150983A1 (en) 2020-01-24 2021-07-29 Ptc Therapeutics Mp, Inc. Methods for treating parkinson's disease with sepiapterin
WO2021168206A1 (en) * 2020-02-19 2021-08-26 Musc Foundation For Research Development L-sepiapterin and methods of use for treating diseases and disorders
CN117157073A (zh) 2021-02-09 2023-12-01 Ptc医疗Mp公司 用墨蝶呤治疗胶质母细胞瘤的方法
WO2022173823A1 (en) 2021-02-09 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
KR20240064728A (ko) 2021-09-29 2024-05-13 피티씨 테라퓨틱스, 인크. 세피아프테린의 제약 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520574A (ja) * 2004-11-17 2008-06-19 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンの安定性錠剤処方物
WO2011132435A1 (ja) * 2010-04-22 2011-10-27 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
JP2011530540A (ja) * 2008-08-12 2011-12-22 オルファ スイス ゲーエムベーハー テトラヒドロビオプテリンを含有する医薬剤形
JP2019535836A (ja) * 2016-11-29 2019-12-12 センサ ファーマシューティカルズ インコーポレイテッドＣｅｎｓａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． セピプテリン及びその塩の多形

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5753656A (en) 1994-08-05 1998-05-19 Suntory Limited Method for treating spinocerebellar degeneration
EP0854934A4 (en) 1995-08-18 2000-09-06 Donald W Landry DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
KR20060120147A (ko) 2003-10-31 2006-11-24 알타나 파마 아게 호흡 질환의 치료를 위한 ｂｈ4의 용도
ES2755334T3 (es) 2003-11-17 2020-04-22 Merck & Cie Proceso para la preparación de formas cristalinas B de clorhidrato de (6R)-L-eritro-tetrahidrobiopterina a partir de otras formas cristalinas
WO2005049000A2 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Treatment of phenylketonurias with bh4
EP1776364A2 (en) 2003-11-17 2007-04-25 BioMarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
CA2588994A1 (en) 2004-12-08 2006-06-15 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
PT1877370E (pt) 2005-04-28 2009-06-02 Asubio Pharma Co Ltd Método para produzir derivados hidrazona
US20080075666A1 (en) * 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
AU2008240259C1 (en) 2007-04-11 2022-11-24 Biomarin Pharmaceutical Inc. Tetrahydrobiopterin compositions and methods of measuring
WO2009113696A1 (en) 2008-03-10 2009-09-17 Takeda Pharmaceutical Company Limited Crystal of benzimidazole compound
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
KR20140021585A (ko) 2011-03-01 2014-02-20 루비콘 리서치 피브이티. 엘티디. 테트라하이드로바이옵테린의 안정한 조성물
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US9181254B2 (en) 2012-05-07 2015-11-10 Shiratori Pharmaceutical Co., Ltd. Method for producing sepiapterin and tetrahydrolactoylpterin
PL2926805T3 (pl) * 2014-03-31 2016-12-30 Stałe kompozycje farmaceutyczne zawierające pochodne biopteryny oraz zastosowania takich kompozycji
EP3468534A4 (en) 2016-06-13 2020-02-05 Meharry Medical College MODULATION OF THE NITRIC OXIDE SYNTHASE PATHWAY FOR ORAL HEALTH
US20190167598A1 (en) * 2016-07-29 2019-06-06 Dipharma S.A. A novel treatment regimen involving sapropterin dihydrochloride
WO2018102314A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
BR112020003865A8 (pt) 2017-09-01 2022-08-16 Censa Pharmaceuticals Inc Composições farmacêuticas compreendendo sepiapterina e seus usos
MX2020012978A (es) 2018-05-30 2021-04-28 Ptc Therapeutics Mp Inc Sales de sepiapterina farmacéuticamente aceptables.
SMT202400430T1 (it) 2018-05-30 2024-11-15 Ptc Therapeutics Mp Inc Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
SMT202500089T1 (it) 2019-08-05 2025-03-12 Univ Virginia Commonwealth Uso di sepiapterina e suoi metaboliti per trattare una esposizione alle radiazioni
LT4034122T (lt) 2019-09-25 2025-11-10 Hiperfenilalaninemijos gydymo būdai

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520574A (ja) * 2004-11-17 2008-06-19 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリンの安定性錠剤処方物
JP2011530540A (ja) * 2008-08-12 2011-12-22 オルファ スイス ゲーエムベーハー テトラヒドロビオプテリンを含有する医薬剤形
WO2011132435A1 (ja) * 2010-04-22 2011-10-27 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
JP2019535836A (ja) * 2016-11-29 2019-12-12 センサ ファーマシューティカルズ インコーポレイテッドＣｅｎｓａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． セピプテリン及びその塩の多形

Also Published As

Publication number Publication date
CN111491635A (zh) 2020-08-04
US20200061070A1 (en) 2020-02-27
US11752154B2 (en) 2023-09-12
EP3675863A4 (en) 2021-01-27
EP3675863A1 (en) 2020-07-08
CA3073957A1 (en) 2019-03-07
JP2023116556A (ja) 2023-08-22
WO2019046849A1 (en) 2019-03-07
BR112020003865A8 (pt) 2022-08-16
US12213982B2 (en) 2025-02-04
US20240100054A1 (en) 2024-03-28
MX2020002271A (es) 2020-10-05
BR112020003865A2 (pt) 2020-09-08
US20250195526A1 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
US12213982B2 (en) Pharmaceutical compositions comprising sepiapterin and uses thereof
JP7778477B2 (ja) セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) セピアプテリン血漿曝露を増加させるための方法
JP7547215B2 (ja) テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法
CN114929682B (zh) 苯并硫代吡喃酮类化合物的盐及其制备方法和用途
HK40087700A (zh) 墨蝶呤的药学上可接受的盐
EA049074B1 (ru) Фармацевтически приемлемые соли сепиаптерина
EA042976B1 (ru) Фармацевтически приемлемые соли сепиаптерина
HK40051961B (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
HK40051961A (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
BR122024013534A2 (pt) Sais e cocristais farmaceuticamente aceitáveis de sepiapterina, composição farmacêutica compreendendo os mesmos, e seus usos
BR112020024346A2 (pt) métodos para aumentar a exposição de sepiapterina no plasma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230531

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230619

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250924